The potential regulatory role of hsa_circ_0004104 in the persistency of atrial fibrillation by promoting cardiac fibrosis via TGF-β pathway

Yuanfeng Gao†, Ye Liu†, Yuan Fu, Qianhui Wang, Zheng Liu, Roumu Hu, Xinchun Yang and Mulei Chen*

Abstract

Introduction: The progression of paroxysmal AF (PAF) to persistent AF (PsAF) worsens the prognosis of AF, but its underlying mechanisms remain elusive. Recently, circular RNAs (circRNAs) were reported to be associated with cardiac fibrosis. In case of the vital role of cardiac fibrosis in AF persistency, we hypothesize that circRNAs may be potential regulators in the process of AF progression.

Materials and methods: 6 persistent and 6 paroxysmal AF patients were enrolled as derivation cohort. Plasma circRNAs expressions were determined by microarray and validated by RT-PCR. Fibrosis level, manifested by serum TGF-β, was determined by ELISA. Pathways and related non-coding RNAs involving in the progression of AF regulated were predicted by in silico analysis.

Results: PsAF patients showed a distinct circRNAs expression profile with 92 circRNAs significantly dysregulated (fold change ≥ 2, p < 0.05), compared with PAF patients. The validity of the expression patterns was subsequently validated by RT-PCR in another 60 AF patients (30 PsAF and PAF, respectively). In addition, all the 5 up and down regulated circRNAs were clustered in MAPK and TGF-beta signaling pathway by KEGG pathway analysis. Among the 5 circRNAs, hsa_circ_0004104 was consistently downregulated in PsAF group (0.6 ± 0.33 vs 1.46 ± 0.41, p < 0.001) and predicted to target several AF and/or cardiac fibrosis related miRNAs reported by previous studies. In addition, TGF-β1 level was significantly higher in the PsAF group (5560.23 ± 1833.64 vs 2236.66 ± 914.89, p < 0.001), and hsa_circ_0004104 showed a significant negative correlation with TGF-β1 level (r = −0.797, p < 0.001).

Conclusion: CircRNAs dysregulation plays vital roles in AF persistency. hsa_circ_0004104 could be a potential regulator and biomarker in AF persistency by promoting cardiac fibrosis via targeting MAPK and TGF-beta pathways.

Keywords: Circular RNAs, Atrial fibrillation, Progression, Biomarkers
greater morbidity and mortality than paroxysmal AF. As we know, the current strategy to curb the progression of AF only depend on modulation of known clinical factors or complications like heart failure and hypertension [3]. Hence, better understanding of the mechanisms and pivotal mediators of this process would be of great opportunities to provide novel targets for preventing or even reversing the progression of AF.

As an emerging class of non-coding RNAs, circular RNAs (circRNAs) have been reported to be involved in various human diseases including cancers and cardiovascular disease like atherosclerosis [4], hypertension [5], and heart failure [6]. But none of the current studies have focused on their roles in the pathogenesis of atrial fibrillation. Some studies have shown a potential role of circRNAs in the process of myocardial fibrosis [7, 8], which is one of the long-recognized mechanisms of cardiac structural remodeling and thus the initiation and progression of AF [9]. Among these studies, most of the identified circRNAs are competing endogenous RNAs (ceRNAs) that act as molecular sponges for miRNAs and thus regulate gene transcription. Therefore, we hypothesize that circRNAs could be potential mediators in the process of AF progression. Based on comparing the circRNAs expression profile between paroxysmal and persistent AF, the present study aims to figure out whether circRNAs are associated with AF progression and the potential mechanism of their roles in this process.

Materials and methods

Study population and data collection

6 patients with paroxysmal AF (PAF) and 6 with persistent AF (PsAF) were enrolled for circRNA microarray analysis. Another 30 pairs of paroxysmal and persistent AF patients were used for RT-PCR for circRNAs and ELISA for TGF-β1. The routine clinical assessment was performed on every patient, including history, physical examination, serial 12-lead ECG monitoring, pulse oximetry, chest radiography and bedside echocardiogram. PAF was diagnosed with AF episodes that were self-terminating or converted within 7 days. Persistent PsAF was classified as AF that lasted longer than 7 days, including episodes that were terminated by cardioversion after 7 days or more. Blood samples from each consenting patient were drawn into EDTA tubes at administration and afterwards processed within 4 h before being stored at – 80 °C.

Ethics approval was obtained by the Ethics Committees of Chaoyang Hospital affiliated to Capital Medical University (2017-2-17-20). Blood sample was collected from each participant at the time of the admission. Informed consent was obtained from each subject. The methods were carried out in accordance with the relevant guidelines, including any relevant details. All analyses were carried out blinded to clinical data.

RNA extraction, library preparation and microarray

TRizol method (Invitrogen, Carlsbad, CA) was used to isolate total RNAs from peripheral plasma samples according to instructions. We used Nano Drop ND-1000 spectrophotometer (Nano Drop Thermo, Wilmington, DE) to evaluate the quantity and quality of RNA. Agarose gel electrophoresis were used to assess the integrity of RNA.

To remove linear RNAs and enrich circRNAs, isolated RNAs were digested with Rnase R (Epicientre, Inc.). Then, we amplified the enriched circRNAs and transcribed them into fluorescent cRNA utilizing a random priming method (Arraystar Super RNA Labeling Kit; Arraystar). RNeasy Mini Kit (Qiagen) was used to purify the labeled circRNAs. Each labeled circRNA (1 μg) was fragmented by adding 10 × Blocking Agent (5 μl) and 25 × fragmentation buffer (1 μl), after heated the mixture at 60 °C for half-hour, we added 2 × hybridization buffer (25 μl) to dilute the labeled circRNA. We dispensed hybridization solution (50 μl) into the gasket slide and assembled to the circRNA expression microarray slide. In an Agilent Hybridization Oven, the slides were incubated at 65 °C for 17 h. The hybridized arrays were washed, fixed and scanned (Agilent Scanner G2505C). The circRNA ID in circBase (http://circbase.mdc-berlin.de) were used as the formal name in the present study.

R software and Bioconductor package was used to quantile normalization and subsequent data processing. Target circRNAs were then retained for further differential analysis. Profile differences and the fold change (i.e. the ratio of the group averages) between two groups (PsAF versus PAF) for each circRNA was compared. Paired t test was used to analyze the statistical difference. CircRNAs having fold changes > 2 and p value < 0.05 were selected as the significantly differentially expressed.

circRNA-miRNA interaction prediction

We predicted the circRNA-miRNA interaction using Arraystar’s home-made miRNA target prediction software based on TargetScan and miRanda. To establish circRNA-miRNA network, MREs on circRNAs were searched using the software, and then selected the miRNAs accordingly. Finally, top 5 miRNA candidates were determined based on miSVR scores (comprehensive modeling of miRNA targets predicts functional non-conserved and non-canonical sites).

circRNA-miRNA-mRNA network

TargetScan, miRDB and miRTarBase were used to predict candidate target genes for miRNA. Functions and
KEGG pathways of those target genes were annotated using KOBAS 3.0. Cytoscape 3.6.0 was used to illustrate circRNA-miRNA-mRNA network map.

Quantitative real-time PCR (qPCR)
SuperScriptTM III Reverse Transcriptase (Invitrogen, Carlsbad, CA) was used for synthesizing cDNA according to manufacturer's instructions. ViiA 7 Real-time PCR System (Applied Biosystems) was used to evaluate the expression level of the circRNAs. Specific divergent primers were designed to amplify the circular transcripts. PCR was performed in 10 μl reaction volume, including cDNA 2 μl, 2 × master mix 5 μl, forward primer (10 μM) 0.5 μl, reverse primer (10 μM) 0.5 μl and double distilled water 2 μl. We first set pre-denaturation reaction at 95 °C for 10 min, then set the reaction at 95 °C for 10 s and at 60 °C for 60 s, repeating 40 cycles. Both target and reference (β-actin) were amplified in triplicate wells. 2−ΔΔ ct method was used to calculate the relative level of each circRNA.

Enzyme linked immunosorbent assay (ELISA)
We used ELISA method with Human Transforming Growth Factor Beta 1 ELISA Kit (Elabscience Biotechnology Co.,Ltd) to measure the plasma level of TGF-β1.The ELISA kit was balanced at room temperature for 20 min according to the instruction. 100 μl plasma sample was added to reaction wells and incubated at 37 °C for 90 min. 100 μl fresh biotinylated antibody working solution was added into the sections and further incubated at 37 °C for 60 min. 100 μl fresh enzyme combination reaction working fluid was introduced to each section after washing, and incubated at 37 °C for half-hour. The plate was rinsed 3 times and added with 100 μl TetraMethyl benzidine (TMB) substrate solution, and further incubated at 37 °C in shade for 15 min. In order to terminate the reaction, the stop solution was added immediately. The optical density (OD) value of each tube was determined within 3 min using a multi-mode microplate reader (MULTIS-KAN EX PRIMARY EIA V. 2.3) at 450 nm, and the content of TGF-β1 in the plasma was analyzed.

Statistical analysis
The normal distribution of continuous variables was evaluated by Kolmogorov–Smirnov test. Normally-distributed continuous variables were expressed in mean ± standard deviation and analyzed by Student's t-test. Binary or categorical variables were expressed in numbers (%). Comparison of continuous variables used independent sample t-test. Comparison of categorical variables used with Chi-square tests. Correlation between two continuous variables was calculated using linear regression. All tests were two-sided and p < 0.05 were considered to be significant. Higher threshold (fold change ≥ 2, p < 0.05) for significance and biological replications by qPCR were carried out to control the potential false discovery of micro-array analysis. Statistical analysis was carried out using SPSS statistics v21.0, GraphPad Prism 5 (GraphPad Software, San Diego, CA).

Results
PsAF patients showed a distinct circRNAs expression pattern compared to PAF patients
To investigate the potential role of circRNAs in different AF types, we utilized human circRNA microarray to quantify the expression differences in peripheral blood plasma between 6 paroxysmal and 6 persistent AF patients. There were no significant differences between two groups on the clinical characteristics or AF risk factors (Table 1), which eliminate potential confounding factors affecting the circRNA expression or contributing to the AF progression.

As seen in the volcano plots (Fig. 1a) and heatmap (Fig. 1b), the circRNA expression profile was distinct between PAF and PsAF patients. To be specific, 92 circRNAs were significantly dysregulated (fold change ≥ 2, p < 0.05), with 76 down-regulated circRNAs and 16

| Table 1 Baseline characteristics of PAF and PsAF patients | PsAF (n = 6) | PAF (n = 6) | p value |
|----------------------------------------------------------|-------------|-------------|---------|
| Age, years                                               | 59.33 ± 6.09 | 58.67 ± 4.89 | 0.838   |
| Male, n (%)                                              | 5 (50.0)    | 3 (50.0)    | 1.000   |
| BMI, kg/m²                                                | 27.25 ± 1.47 | 25.45 ± 2.33 | 0.140   |
| Heart rate, bpm                                           | 95.50 ± 18.21 | 87.00 ± 18.22 | 0.438   |
| CAD, n (%)                                               | 0 (0)       | 1 (16.7)    | 1.000   |
| HTN, n (%)                                               | 5 (83.3)    | 4 (66.7)    | 1.000   |
| DM, n (%)                                                | 2 (33.3)    | 1 (16.7)    | 1.000   |
| Smoke, n (%)                                             | 2 (33.3)    | 0 (0)       | 0.455   |
| AF duration, months                                       | 9.2 ± 2.7   | 7.8 ± 3.1   | 0.291   |
| LAD, mm                                                  | 38.83 ± 5.67 | 39.00 ± 3.90 | 0.954   |
| LVEF, %                                                  | 64.50 ± 4.46 | 68.67 ± 5.39 | 0.175   |
| LVEDD, mm                                                 | 46.00 ± 4.05 | 47.92 ± 3.01 | 0.374   |
| HbA1c, %                                                 | 6.18 ± 1.03 | 5.86 ± 0.46 | 0.507   |
| LDL, mmol/L                                              | 2.80 ± 0.42 | 2.87 ± 1.58 | 0.922   |
| Creatine, μmol/L                                         | 64.98 ± 20.70 | 63.02 ± 17.55 | 0.863   |
| BNP, pg/ml                                               | 1336.17 ± 806.4 | 1211.02 ± 741.18 | 0.385   |
| β-blockers, n (%)                                         | 4 (66.7)    | 3 (50.0)    | 1.000   |

Data are number (%) and mean ± SD
PsAF, persistent atrial fibrillation; PAF, paroxysmal atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; HbA1c, glycosylated hemoglobin; LDL, low density lipoprotein
circRNAs up-regulated in PsAF group compared to PAF group.

**Biological replication confirmed the consistency of the microarray results**

We selected > twofold change and p < 0.01 in circRNAs for more stringent significance. Besides, potential candidates were excluded when effective primers could not be designed. The expression of 7 circRNAs were assessed by qPCR in another 20 subjects (10 PAF and 10 PsAF, respectively) recruited for validation (biological replication). For these circRNAs, qPCR replicated five out of the seven circRNAs (hsa_circ_0006577, hsa_circ_0004104, hsa_circ_0001568, hsa_circ_0001204, hsa_circ_0000511) as statistically significant in the samples, while the other two showed a too low abundance to quantify (Fig. 2).

**Multiple miRNAs targeting TGF-beta pathways were predicted to be sponged by the dysregulated circRNAs**

To elucidate the function of selected circRNAs, targeted miRNAs were predicted with Arraystar’s home-made miRNA target prediction software based on TargetScan and miRanda (see details in method part). Targeted miRNAs were ranked according to the mirSVR scores, thereby identifying the top 5 ranking candidates for further analysis. Top 5 predicted miRNAs of selected
circRNAs were used for prediction of target genes using TargetScan, miRanda, and miRTarBase combined. For up-regulated circRNAs, hsa_circ_0001568 and hsa_circ_0001204, 333 target genes were predicted in all three databases (Fig. 3a). For down-regulated circRNAs, hsa_circ_0006577, hsa_circ_0004104, and hsa_circ_0000511, 493 target genes were incorporated in all three databases (Fig. 3b). CircRNA-miRNA-mRNA network and genes directly targeting TGF-β1 signaling pathway were illustrated on Fig. 4a, b. 3 genes (ACVR2A, ACVR1B, and ID4) from down-regulated circRNAs and six genes (TGFBR1, TGFBR2, TGFBR3) from up-regulated circRNAs targeted TGF-beta signaling pathway.

Functional annotations were carried out with KOBAS 3.0 to generated significant GO term and KEGG signaling pathways (FDR < 0.05). For up-regulated circRNAs, GO annotations were mainly clustered in nucleus, cytoplasm, and nucleoplasm in cellular component (CC); peptidyl-tyrosine dephosphorylation, positive regulation of transcription from RNA polymerase II promoter, and positive regulation of transcription, DNA-templated in biological process (BP). And protein tyrosine phosphatase activity, protein binding, and protein tyrosine/threonine phosphatase activity in molecular function (MF). KEGG pathways for those miRNAs clustered in MAPK signaling pathway, Endocytosis, TGF-beta signaling pathways and Huntington’s disease. For down regulated circRNAs, GO annotations were mainly clustered in focal adhesion, membrane, and extracellular matrix in CC; pathway-restricted SMAD protein phosphorylation, transforming growth factor beta receptor signaling pathway, and collagen fibril organization in BP. In addition, SMAD binding, type II transforming growth factor beta-receptor binding, and transforming growth factor beta-activated receptor activity in MF. KEGG pathways for those miRNAs clustered in AGE-RAGE signaling pathway in diabetic complications, MAPK signaling pathway, ErbB signaling pathway, PI3K-Akt signaling pathway, Axon guidance, FoxO signaling pathway, and TGF-beta signaling pathway. As was shown in Fig. 5, both up and down regulated circRNAs clustered in MAPK and TGF-beta signaling pathway.

**TGF-β1 pathway was significantly activated in PsAF patients**

The genomic locus of exonic hsa_circ_0004104 was on chromosome 5. The top 5 predicted miRNA targets of
hsa_circ_0004104 were hsa-miR-194-3p, hsa-miR-22-5p, hsa-miR-342-5p, hsa-miR-328-3p, and hsa-miR-30d-3p. Among them, hsa-miR-328-3p and hsa-miR-30d-3p were reported to correlate with TGF-beta signaling pathway and structural remodeling in atrial fibrillation. Besides, serum TGF-β1 level has been recognized as surrogate of cardiac fibrosis. In view of that the results above, we further quantified the serum hsa_circ_0004104 and TGF-β1 level in an expanded sample size of 30 persistent vs 30 paroxysmal AF patients. Two groups showed no significant difference in clinical profiles (Table 2), while patients with PsAF expressed significantly lower level of hsa_circ_0004104 (0.6 ± 0.33 vs 1.46 ± 0.41, p < 0.001). As seen in Fig. 6a, TGF-β1 level was significantly higher in the PsAF group (5560.23 ± 1833.64 vs 2236.66 ± 914.89, p < 0.001), indicating a potential higher level of cardiac fibrosis. In addition, hsa_circ_0004104 showed a significant reverse correlation with TGF-β1 level (r = -0.797, p < 0.001) by Linear regression analysis (Fig. 6b), in both of the PAF (r = -0.421, p = 0.02) and PsAF (r = -0.665, p < 0.001) patients.

Discussion

Atrial fibrosis has long been known to associate with the persistence of AF in both animal models and human studies [10]. The present study provided further evidence for this hypothesis from the perspective of non-coding RNAs, to be specific, circRNAs by a hypothesis free measure (microarray). There are several strengths of the present study: (1) this was the first interrogation of the human plasma circRNAs signature and its potential functional impact on the progression of AF; (2) MAPK and TGF-beta signaling pathway were indicated to involve in the progression of atrial fibrillation; (3) circRNAs could be involved in the AF progression by promoting cardiac fibrosis.

The natural history of AF was progression from self-terminating paroxysms to a more sustained state [10]. Several clinical variables have been previously associated with AF progression, including age, diabetes, valvular heart disease, heart failure, heart rate and an increased left atrial (LA) enlargement [11]. Atrial Structural remodeling or fibrotic atrial cardiomyopathy was reported to be related to paroxysmal AF progression [12]. The presence of interstitial fibrosis could lead to changes in cellular coupling resulting in spatial ‘non-uniform anisotropic’ impulse propagation atrial activation abnormalities. This process underlies the initiation and perpetuation of AF [13]. Fibrotic structural remodeling could be attributed to activation of several pathways fine-tuned by different types of modulating factors. Mitogen-activated protein kinase (MAPK) signaling pathway was crucial in the process of atrial fibrosis. Tsai CF et al. reported that aldosterone significantly increased activation of p38 MAPK pathways and increased expression of fibrotic marker proteins like transforming growth factor (TGF)-β1 and α-smooth muscle actin (SMA) [14]. In addition, Jinqi Fan have reported that over expression of ACE2 would inhibit MAPK activation, decrease TGF-β1 and attenuate atrial fibrosis [15]. Experimental studies have also demonstrated the possible roles of miRNAs in AF progression [16]. Takeshi Soeki et al. studied intra cardiac blood samples from AF and sinus rhythm and discovered higher level of miRNA-328 in AF patients. Level of miR-328 showed a positive correlation with the LA voltage zone index and might be involved in the process of atrial remodeling [17]. Another micro RNA, miR-30 was found to elevate in cardiomyocytes from AF patients [18], and was related to diffuse myocardial fibrosis [19]. MiR-328 was reported to target CACNA1C/Cav1.2 [20] and miR-30d could target KCNJ3/Kir3.1 [18], which could lead
Fig. 4 Prediction of target genes and circRNA-miRNA-mRNA network. **a** circRNA-miRNA-mRNA network for up regulated circRNAs. Genes targeting TGF-β1 signaling pathway were illustrated with purple color. **b** circRNA-miRNA-mRNA network for down regulated circRNAs. Genes targeting TGF-β1 signaling pathway were illustrated with purple color.
to adverse electrical remodeling in atrial fibrillation. In the present study, the circRNAs signature showed a significant different pattern between PAF and PsAF, which indicate that circRNAs expression change could involve in the process of AF progression from paroxysmal to persistent AF. In addition, the significantly down-regulated circRNA hsa_circ_0004104 was predicted to target these two AF-relating miRNAs (miR-30 and miR-328), indicating that the potential functional impact of circRNAs could be its upstream regulatory effect.

A major mechanism of circRNAs in the regulation of cell function was to act as miRNA sponges [21]. Recently reported circRNA_010567 could promote myocardial fibrosis via suppressing miR-141 by targeting TGF-β1 [8]. Similarly, over-expression of circRNA_000203 was reported to have the capacity of eliminating the anti-fibrosis effect of miR-26b-5p in cardiac fibroblasts [7]. The results of our study added yet another example of the sponge effect of circRNAs in the process of disease.

Besides, due to its stability endowed by its molecular structure, circRNAs had been proposed to be potential biomarkers for cardiovascular diseases [22]. In the present study, we found that the circRNA hsa_circ_0004104 was down-regulated both by microarray and RT-PCR validation. In addition, it showed a reverse association with the known marker of atrial fibrosis TGF-β1. These in all indicated a potential biomarker for the circRNA hsa_circ_0004104 in the prediction of AF progress.

The top 5 miRNAs targeted by hsa_circ_0004104 were all reported to affect the TGF-β1 pathway. MiR-328 from cardiomyocytes could enhance collagen deposition and provoke cardiac fibrosis by activation of TGF-β1 pathway.

Table 2 Demographics of PAF and PsAF patients for circRNA expression validation and serum TGF-β1 level quantification

| Term                  | Regulation | PsAF (n = 30) | PAF (n = 30) | p value |
|-----------------------|------------|---------------|--------------|---------|
| MAPK signaling pathway| Up         | 64 ± 9.46     | 63.67 ± 5.74 | 0.87    |
| PI3K-Akt signaling pathway| Up      | 22 (73.3)     | 21 (70)      | 0.774   |
| AGE-RAGE signaling pathway in diabetic complications| Up       | 27.28 ± 3.82  | 26.49 ± 4.07 | 0.452   |
| Axon guidance         | Up         | 88.77 ± 17.51 | 83.37 ± 23.88| 0.322   |
| FoxO signaling pathway| Up         | 9 (30)        | 5 (16.7)     | 0.222   |
| TGF-beta signaling pathway| Up       | 18 (60)       | 20 (66.7%)   | 0.592   |
| Huntington’s disease  | Up         | 7 (23.3)      | 9 (30)       | 0.559   |
| Endocytosis           | Up         | 8 (26.7)      | 9 (30)       | 0.627   |
| Aging, months         | Down       | 143 ± 2.6     | 84 ± 2.9     | 0.056   |
| LAD, mm               | Down       | 42.43 ± 4.35  | 40.72 ± 4.65 | 0.61    |
| LVEF, %               | Down       | 63 ± 7.77     | 63.53 ± 4.66 | 0.787   |
| LVEDD, mm             | Down       | 48.8 ± 4.05   | 49.2 ± 4.31  | 0.712   |
| HbA1C, %              | Down       | 6.43 ± 1.02   | 5.81 ± 1.9   | 0.126   |
| LDL, mmol/L           | Down       | 2.25 ± 0.84   | 2.56 ± 0.82  | 0.156   |
| Creatine, µmol/L      | Down       | 74.15 ± 16.19 | 71.56 ± 17.13| 0.55    |
| BNP, pg/ml            | Down       | 1506.82 ± 719.46 | 1142.11 ± 782.98 | 0.185 |
| β-blockers, n (%)     | Down       | 21 (70)       | 20 (66.7%)   | 0.603   |
| ACEI/ARB, n (%)       | Down       | 11 (36.7)     | 13 (43.3)    | 0.511   |
| hsa_circ_0004104      | Down       | 0.6 ± 0.33    | 1.46 ± 0.41  | <0.001  |
| TGF-β1, pg/ml         | Down       | 5560.23 ± 1833.64 | 2236.66 ± 914.89 | <0.001  |

Data are number (%) and mean ± SD

PsAF, persistent atrial fibrillation; PAF, paroxysmal atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; HbA1C, glycosylated hemoglobin; LDL, low density lipoprotein; BNP, brain natriuretic peptide; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin Receptor Blocker; TGF-β1, Transforming growth factor-beta 1

Fig. 5 Signaling pathway for dysregulated circRNAs predicted from miRNA target genes. Both up and down regulated circRNAs clustered in MAPK and TGF-beta signaling pathway. Input number refers to number of gene count clustered in each term. Color shows -lgFDR as an attribute.
in a mouse AF model [23]. Meantime, demethylation of miR-30d precursor gene and restoration of miR-30d would inhibit effects of TGF-β1. Other miRNAs that were significantly targeted by the circRNA hsa_circ_0004104, like miR-29 [24], miR-19a-3p/19b-3p [25], and miR-208a [26] were all reported to modulate TGF-β1. Fortunately, TGF-β1 was a secretory protein which could be detected in serum. We further investigated the serum level of TGF-β1 to lend some evidence for the functional impact of the circRNA hsa_circ_0004104 in the progression of AF. It turned out that hsa_circ_0004104 correlated with the expression of serum TGF-β1, which added a concrete strength to the role of hsa_circ_0004104 in the TGF-beta signaling pathway predicted by in silico analysis and thus AF progression.

Recently, a study by Wang LY profiled transcriptome-wide circRNAs expression in peripheral blood mononuclear cells (PBMCs) of patients with and without coronary artery disease (CAD), after validating in a large cohort, two circRNAs, hsa_circ_0004104 and hsa_circ_0001879, were found to be diagnostic biomarkers for CAD [27]. The study also demonstrated that hsa_circ_0004104 may contribute to the pathogenesis of CAD by upregulating of atherosclerosis-susceptible genes, such as IDO1, MMP8,

![Fig. 6](image_url) # Expression levels of TGF-β1 in two AF groups. Correlation between hsa_circ_0004104 and TGF-β1. a PsAF patients had significantly higher level of TGF-β1 than PAF, p < 0.001. b Negative correlation between hsa_circ_0004104 and TGF-β1 verified by linear regression (r = -0.797, p < 0.001). Larger bubble size referred to higher level of plasma TGF-β1. ***(p < 0.001)
CD40, and downregulating of anti-atherosclerosis genes, such as ApoA1, RNASE1 [27]. However, the mechanisms by which hsa_circ_0004104 regulate the progression of PAF to PsAF remain elusive. We found the genomic locus of exonic hsa_circ_0004104 was on chromosome 5, nearby the secreted protein acidic and rich in cysteine (SPARC) gene, and SPARC was proved to be an important role in cardiac repair and fibrosis previously [28]. Hsa_circ_0004104 may regulate the progression of AF by affecting the expression of SPARC gene, this hypothesis, however, needs further experimental validation.

The present study suffers from several limitations: (1) there were no in vitro study of the candidate circRNA regarding its effects in the atrial cells; (2) the sample size of the validation groups was relatively small; (3) to establish the biomarker role of hsa_circ_0004104 in predicting AF progression, a cohort study following the PAF patients was needed. Despite of these drawbacks, the present study still provides novel proposals and preliminary data that shed light on the role of circRNAs in the important but under-researched area of AF persistence.

Conclusion
To sum up, the present study found significant differentiated expression patterns of circRNAs between paroxysmal and persistent AF. This indicates the potential role of circRNAs dysregulation in the process of cardiac fibrosis as well as AF progression. Besides, the results of in silico analysis and in vivo studies also indicated that circRNA hsa_circ_0004104 could be a potential regulator and biomarker in the persistence of AF by promoting cardiac fibrosis via targeting MAPK and TGF-beta pathway.

Abbreviations
AF: Atrial fibrillation; PAF: Paroxysmal AF; PsAF: Persistent AF; MiRNA: MicroRNA; CircRNA: Circular RNA; CeRNA: Competing endogenous RNA; qPCR: Quantitative real-time PCR; ELISA: Enzyme linked immunosorbent assay; TMB: TetraMethyl benzidine; OD: Optical density; LA: Left atrial; MAPK: Mitogen-activated protein kinase; TGF-β: Transforming growth factor-beta; SMA: α-Smooth muscle actin; PBMCs: Peripheral blood mononuclear cells; CAD: Coronary artery disease; SPARC: Secreted protein acidic and rich in cysteine.

Acknowledgements
Not applicable.

Authors’ contributions
Dr. YFG, Dr. YF, and Dr. YL participated in the design, conducted data analysis and drafted the manuscript; they contributed equally to this article. Dr. QHW collected and analyzed part of the data. Dr. ZL and RMH provided technical support and commented on the manuscript drafts. Dr. XCY and MLC aided collected and analyzed part of the data. Dr. ZL and RMH provided technical support and commented on the manuscript drafts. Dr. QHW, Dr. YF and Dr. YL participated in the design, conducted data analysis and drafted the manuscript, they contributed equally to this article. Dr. QHW and Dr. YFG are the co-first authors of this manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to the restrictions by the Beijing Chaoyang Hospital but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the institutional review board of Beijing Chaoyang Hospital and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent forms were obtained from all participants and their legal relatives. The raw data are available from the corresponding author on reasonable request, with no administrative permissions required.

Consent to publication
Not applicable.

Competing interests
None.

Received: 12 August 2020 Accepted: 1 January 2021
Published online: 09 January 2021

References
1. Chugh SS, Havmoeller R, Narayan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, Mcaulay JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hendricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.
3. de Vos CB, Pisters R, Nieuwaard R, Prins MH, Tieleman RG, Coelen RJ, van den Heijjant AC, Alesse MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725–31.
4. Holdt LM, Stahringer A, Soss K, Pichler G, Kilan NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolau A, Gabel B, Unertl F, Scholz M, Thiery J, Musunuru K, Bohn R, Mann M, Teupser D. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
5. Bao X, Zheng S, Mao S, Gu T, Liu S, Sun J, Zhang L. Potential risk factor of essential hypertension in case-control study. Circular RNA hsa_circ_0037911. Biochem Biophys Res Commun. 2018;498(4):789–94.
6. Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, Zhou Y, Sun T, Wang M, Yu T, Gong Y, Liu J, Deng YH, Li N, Li P. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J. 2016;37(33):2602–11.
7. Tang CM, Zhang M, Huang L, Hu ZQ, Zhao JN, Xiao Z, Zhang Z, Lin XQ, Zheng XL, Yang M, Wu SL, Cheng JD, Shan Z. CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing the target of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Sci Rep. 2017;7:40342.
8. Zhou B, Yu JW. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-beta1. Biochem Biophys Res Commun. 2017;484(4):769–75.
9. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2016;63(22):2335–45.
10. Shukla A, Curtis AB. Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. Vasc Health Risk Manag. 2014;10:1–12.
11. Padfield GJ, Steinberg C, Swampillai J, Qian H, Connolly SJ, Dorian P, Green MS, Humphries KH, Klein GJ, Shieldon R, Talajic M, Kerr CR. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm. 2017;14(6):801–7.
12. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34(35):2731–8.
13. Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Pacing Clin Electrophysiol. 1997;20(2 Pt 2):397–413.

14. Tsai CF, Yang SF, Chou CJ, Hung HC, Wang CL, Hong CJ. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol. 2013;169(1):17–28.

15. Fan J, Zou L, Cui W, Liu H, Hu Y, Chen S, Ling Z, Zhang Q, Zhang B, Lan X, Su L, Zrenner B, Yin Y. Atrial overexpression of angiotensin-converting enzyme 2 improves the canine rapid atrial pacing-induced structural and electrical remodeling. Fan, ACE2 improves atrial substrate remodeling. Basic Res Cardiol. 2015;110(4):45.

16. Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res. 2011;89(4):710–21.

17. Soeki T, Matsuura T, Bando S, Tobiie T, Uematsu E, Ise T, Kusunose K, Yamaguchi K, Yagi S, Fukuda D, Yamada H, Wakatetsu T, Shimabukuro M, Sata M. Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation. J Cardiovasc Res. 2016;68(6):472–7.

18. Morishima M, Iwata E, Nakada C, Tsukamoto Y, Takanari H, Miyamoto S, Moriyama M, Ono K. Atrial fibrillation-mediated upregulation of miR-30d regulates myocardial electrical remodeling of the G-protein-gated K+ channel. iKACH. Circ. J. 2016;80(6):1346–55.

19. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009;104(2):170–8 (176p following 178).

20. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Zhang Y, Fan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122(23):2378–87.

21. Tan WL, Lim BT, Anene-Nzelu CG, Acker-Johnson M, Dashi A, See K, Tzang S, Lee DP, Chua WW, Luu TD, Li PY, Richards AM, Foo RS. A landscape of circular RNA expression in the human heart. Cardiovasc Res. 2017;113(3):298–309.

22. Baeumker AM, Aonuma I, Teoh JP, Tang YL, Kim IM. Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases. Acta Pharmacol Sin. 2018;39(11):100–9.

23. Zhao D, Li C, Yan H, Li T, Qian M, Zheng N, Jiang H, Liu L, Xu B, Wu Q, Li X, Liang H, Shan H. Cardiomyocyte-derived miR-328 promotes cardiac fibrosis by paracrine regulating adjacent fibroblasts. Cell Physiol Biochem. 2018;46(4):1555–62.

24. Wang CY, Ren JB, Liu M, Yu L. Targeting miR-29 induces apoptosis of osteosarcoma MG-63 cells via regulation of TGF-beta 1/PUMA signal. Eur Rev Med Pharmacol Sci. 2016;20(7):3552–60.

25. Zou M, Wang F, Gao R, Wu J, Ou Y, Chen X, Wang T, Zhou X, Zhu W, Li P, Qi LW, Jiang T, Wang W, Li C, Chen J, He Q, Chen Y. Autophagy inhibition of hsa-miR-19a-3p/19b-3p by targeting TGF-beta R II during TGF-beta1-induced fibrogenesis in human cardiac fibroblasts. Sci Rep. 2016;6:24747.

26. Wang BW, Wu GJ, Cheng WP, Shyu KG. Mechanical stretch via transforming growth factor-beta1 activates microRNA-208a to regulate hypertrophy in cultured rat cardiac myocytes. J Formos Med Assoc. 2013;112(10):635–43.

27. Wang L, Shen C, Wang Y, Zou T, Zhu H, Lu X, Li L, Yan B, Chen J, Chen S, Lu X, Gu D. Identification of circular RNA Hsa_circ_001879 and Hsa_circ_0004104 as novel biomarkers for coronary artery disease. Atherosclerosis. 2019;286:88–96.

28. Bakshwa AD. The role of secreted protein acidic and rich in cysteine (SPARC) in cardiac repair and fibrosis: does expression of SPARC by macrophages influence outcomes? J Mol Cell Cardiol. 2016;93:156–61.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.